Here are the 424B prospectus supplements from AIM ImmunoTech Inc (AIMI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AIMI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMI filings page.
AIM ImmunoTech Inc. is offering 2,554,119 registered shares of Common Stock at $0.5189 per share. The prospectus supplement describes a concurrent private placement to accredited investors for 771,503 unregistered shares, pre-funded warrants to purchase 1,782,616 shares and Class J warrants to purchase up to 10,216,476 shares. Net proceeds from the registered offering are estimated at approximately $1.2 million after placement agent fees and estimated offering expenses; proceeds are intended to support a planned Phase 3 trial for Ampligen, manufacture clinical drug supply and for working capital. The Common Warrants become exercisable only upon the Stockholder Approval Date and will expire five years thereafter; the Pre-Funded Warrants are exercisable immediately at $0.001 per share. The offering is on a reasonable best efforts basis with no minimum and is subject to lock-ups, placement agent compensation (cash fees and warrants), and NYSE American continued-listing risks.
AIM ImmunoTech Inc. is offering 7,519,351 shares of Common Stock at $0.325 per share pursuant to a prospectus supplement, with estimated net proceeds of approximately $2.2 million.
In a concurrent private placement (exempt from this prospectus), the company is also offering Series I Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share; the warrants become exercisable only upon stockholder approval and expire five years after the Stockholder Approval Date. The offering is being conducted on a reasonable best efforts basis with Ladenburg Thalmann & Co. Inc. acting as sole placement agent.
AIM Immunotech Inc. supplements its prospectus to suspend its at-the-market equity distribution agreement and terminate the continuous offering. The Prospectus had registered the offer and sale of up to $3,409,174 of common stock under an Equity Distribution Agreement with Maxim Group LLC. As of this supplement dated May 19, 2026, the company reports $2,847,151.09 of common stock sold under the EDA and a last reported sale price of $0.4080 per share on May 18, 2026. The supplement states the company will not make any sales under the EDA unless and until a new prospectus supplement is filed; the EDA itself remains in full force and effect.
Amid an existing shelf registration, AIM ImmunoTech, Inc. filed a prospectus supplement dated April 10, 2026 to increase the maximum aggregate offering price under its equity distribution agreement with Maxim Group LLC to $3,409,174. The supplement relies on General Instruction I.B.6 of Form S-3 and notes a public float of $10,227,521 calculated using 8,182,017 shares held by non‑affiliates at $1.25 per share (closing price on February 13, 2026).
The company states it has sold $2,288,758.60 under the instruction during the prior 12 months and is eligible to sell an additional $1,120,415. Sales, if any, may be made as “at the market offerings” through Maxim, which may receive compensation up to 3.0% of gross proceeds. The supplement affirms Maxim will be deemed an underwriter for these sales and that indemnification provisions apply.